Combination of | |
---|---|
Doravirine | Non-nucleoside reverse transcriptase inhibitor |
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
Clinical data | |
Trade names | Delstrigo |
Other names | MK-1439A |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a618049 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [5] [7] It contains doravirine, lamivudine, and tenofovir disoproxil. [8] [7] It is taken by mouth. [5]
In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018. [8] [9] [10]
Combination of | |
---|---|
Doravirine | Non-nucleoside reverse transcriptase inhibitor |
Lamivudine | Nucleoside reverse transcriptase inhibitor |
Tenofovir disoproxil | Nucleotide reverse transcriptase inhibitor |
Clinical data | |
Trade names | Delstrigo |
Other names | MK-1439A |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a618049 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Doravirine/lamivudine/tenofovir, sold under the brand name Delstrigo, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. [5] [7] It contains doravirine, lamivudine, and tenofovir disoproxil. [8] [7] It is taken by mouth. [5]
In the United States, it was approved by the Food and Drug Administration (FDA) for the treatment of HIV-1 infection in August 2018. [8] [9] [10]